In the particular cases of NSCLC, this discordance could also be partially explained by the fact that the overall response rate of gemcitabine in PDA is 5-7% [4] in comparison to the 20% found in NSCLC [38], meaning that lung cancer is intrinsically more sensitive to gemcitabine and levels of RRM1 may play a more relevant role. The gene discussed is RRM1; the disease is lung carcinoma.